[go: up one dir, main page]

WO2000021505A3 - Composition for the parenteral administration of active agents - Google Patents

Composition for the parenteral administration of active agents Download PDF

Info

Publication number
WO2000021505A3
WO2000021505A3 PCT/EP1999/007300 EP9907300W WO0021505A3 WO 2000021505 A3 WO2000021505 A3 WO 2000021505A3 EP 9907300 W EP9907300 W EP 9907300W WO 0021505 A3 WO0021505 A3 WO 0021505A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
parenteral administration
active agents
support material
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/007300
Other languages
German (de)
French (fr)
Other versions
WO2000021505A2 (en
Inventor
Juergen Grande
Silke Schuth
Gitte Boehm
Holger Bengs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Research and Technologies GmbH and Co KG
Original Assignee
Aventis Research and Technologies GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Research and Technologies GmbH and Co KG filed Critical Aventis Research and Technologies GmbH and Co KG
Priority to EP99948917A priority Critical patent/EP1124538A2/en
Priority to CA002346670A priority patent/CA2346670A1/en
Priority to JP2000575481A priority patent/JP2002527376A/en
Priority to AU61989/99A priority patent/AU6198999A/en
Publication of WO2000021505A2 publication Critical patent/WO2000021505A2/en
Publication of WO2000021505A3 publication Critical patent/WO2000021505A3/en
Priority to NO20011670A priority patent/NO20011670L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a composition for the parenteral administration of active agents, containing a support material and at least one active agent. The support material contains spherical microparticles with an average diameter of 1 nm to 100 νm, said particles consisting entirely or partially of at least one water-insoluble linear polysaccharide, especially a linear polyglucan. The invention also relates to a suspension containing this composition, and to the use of the composition.
PCT/EP1999/007300 1998-10-15 1999-10-02 Composition for the parenteral administration of active agents Ceased WO2000021505A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99948917A EP1124538A2 (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active agents
CA002346670A CA2346670A1 (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active compounds
JP2000575481A JP2002527376A (en) 1998-10-15 1999-10-02 Composition for parenteral administration of active substance
AU61989/99A AU6198999A (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active agents
NO20011670A NO20011670L (en) 1998-10-15 2001-04-03 Preparation for parenteral administration of active compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1998147593 DE19847593A1 (en) 1998-10-15 1998-10-15 Parenteral drug administration composition with depot and controlled release comprises active agent and water soluble polysaccharide microparticles as carrier
DE19847593.4 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000021505A2 WO2000021505A2 (en) 2000-04-20
WO2000021505A3 true WO2000021505A3 (en) 2000-09-21

Family

ID=7884587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007300 Ceased WO2000021505A2 (en) 1998-10-15 1999-10-02 Composition for the parenteral administration of active agents

Country Status (8)

Country Link
EP (1) EP1124538A2 (en)
JP (1) JP2002527376A (en)
AU (1) AU6198999A (en)
CA (1) CA2346670A1 (en)
DE (1) DE19847593A1 (en)
NO (1) NO20011670L (en)
PL (1) PL347770A1 (en)
WO (1) WO2000021505A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10022095B4 (en) * 2000-05-08 2005-07-14 Südzucker AG Mannheim/Ochsenfurt Gel of a poly-α-1,4-glucan and starch
DE10119522A1 (en) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Preparation and application of a suspension composition with an ultrasound contrast medium
ES2921427T3 (en) 2004-01-23 2022-08-25 Eden Research Plc Nematode elimination methods that comprise the application of an encapsulated terpene component
ES2434415T3 (en) 2004-05-20 2013-12-16 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods for its manufacture and use.
US20080227805A1 (en) 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328732A1 (en) * 1975-10-21 1977-05-20 Takeda Chemical Industries Ltd B-1,3-GLUCAN POLYSACCHARIDE BEADS
EP0053580A2 (en) * 1980-11-29 1982-06-09 Sandoz Ag Pharmaceutical compositions
WO1995031553A1 (en) * 1994-05-18 1995-11-23 Institut Für Genbiologische Forschung Berlin Gmbh DNA SEQUENCES CODING FOR ENZYMES CAPABLE OF FACILITATING THE SYNTHESIS OF LINEAR α-1,4 GLUCANS IN PLANTS, FUNGI AND MICROORGANISMS
WO1999011695A1 (en) * 1997-08-28 1999-03-11 Aventis Research & Technologies Gmbh & Co Kg Spherical microparticles containing linear polysaccharides
WO1999052506A1 (en) * 1998-04-09 1999-10-21 Axiva Gmbh Particulate active agent support for pulmonary application
WO2000012590A1 (en) * 1998-08-28 2000-03-09 Celanese Ventures Gmbh Method for the production of spherical microparticles consisting totally or partly of at least one water-insoluble polyglucan containing branches and microparticles produced according to said method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2328732A1 (en) * 1975-10-21 1977-05-20 Takeda Chemical Industries Ltd B-1,3-GLUCAN POLYSACCHARIDE BEADS
EP0053580A2 (en) * 1980-11-29 1982-06-09 Sandoz Ag Pharmaceutical compositions
WO1995031553A1 (en) * 1994-05-18 1995-11-23 Institut Für Genbiologische Forschung Berlin Gmbh DNA SEQUENCES CODING FOR ENZYMES CAPABLE OF FACILITATING THE SYNTHESIS OF LINEAR α-1,4 GLUCANS IN PLANTS, FUNGI AND MICROORGANISMS
WO1999011695A1 (en) * 1997-08-28 1999-03-11 Aventis Research & Technologies Gmbh & Co Kg Spherical microparticles containing linear polysaccharides
WO1999052506A1 (en) * 1998-04-09 1999-10-21 Axiva Gmbh Particulate active agent support for pulmonary application
WO2000012590A1 (en) * 1998-08-28 2000-03-09 Celanese Ventures Gmbh Method for the production of spherical microparticles consisting totally or partly of at least one water-insoluble polyglucan containing branches and microparticles produced according to said method

Also Published As

Publication number Publication date
DE19847593A1 (en) 2000-04-20
EP1124538A2 (en) 2001-08-22
WO2000021505A2 (en) 2000-04-20
JP2002527376A (en) 2002-08-27
PL347770A1 (en) 2002-04-22
CA2346670A1 (en) 2000-04-20
AU6198999A (en) 2000-05-01
NO20011670D0 (en) 2001-04-03
NO20011670L (en) 2001-06-12

Similar Documents

Publication Publication Date Title
CA2338358A1 (en) Compounds and compositions for delivering active agents
SI9520106B (en) Modafinil having a defined particle size
CA2200595A1 (en) Use of starch for transdermal applications
MY102037A (en) Hydrosols of pharmacologically active agents and their pharmaceutical compositions
MY111172A (en) Perfume particles.
CA2271636A1 (en) Disinfecting microemulsions
WO2002062881A3 (en) Foam including surface-modified nanoparticles
CA2339765A1 (en) Compounds and compositions for delivering active agents
WO2003024396A3 (en) Dry powder medicament formulations
EP0965343A3 (en) Ziprasidone formulations
EP1210942A3 (en) Microparticles
WO2000020019A3 (en) A composition for the prevention and/or treatment of atherosclerosis
AU7408991A (en) Aqueous cosmetic or dermo-pharmaceutical composition containing, in suspension, hydrated spheroids of a hydrophilic lipidic substance
WO2000021505A3 (en) Composition for the parenteral administration of active agents
WO1998018435A3 (en) Conditioning shampoo composition
ATE190844T1 (en) CEFIXIM PREPARATION
ZA200007633B (en) Pesticide preparations in the form of aqueous suspension.
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
WO2001047474A3 (en) Use of nano-scale deodorants
CA2363156A1 (en) Deodorant compositions
CA2273272A1 (en) Immediate release drug delivery forms
IL139863A0 (en) 3,4-diphenyl bicyclo [4.3.0] nonyl derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
EP1044972A4 (en) 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME
AU6315300A (en) Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO1998033478A3 (en) Rna- and dna-based active agents in nanoparticles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN CZ JP KR NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN CZ JP KR NO NZ PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2346670

Country of ref document: CA

Ref document number: 2346670

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 99812073.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 575481

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09834741

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999948917

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 61989/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999948917

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999948917

Country of ref document: EP